What Paul Reubens' Story Can Help Us Understand About Acute Myeloid Leukemia

What is on the record, and what is not

Paul Reubens died on the night of 30 July 2023, aged 70. The Guardian reported that he had been diagnosed with cancer years earlier, according to his team.

A statement posted after his death, written by Reubens himself, apologized for not going public with what he had been facing over the previous six years.

NBC News obtained his death certificate, issued on 8 September 2023. TODAY reported that it gave the immediate cause of death as acute hypoxic respiratory failure, listed acute myelogenous leukemia as a sequential underlying cause, and listed metastatic lung cancer as another contributor.

That is the extent of the public record. Nothing here describes when he was diagnosed with either cancer, what treatment he had, or in what order things happened, because the reporting does not say.

Reading a death certificate without over-reading it

A death certificate is a sequence, not a story.

The immediate cause is the final event. Acute hypoxic respiratory failure means the body could not get enough oxygen into the tissues, and it happened quickly.

Underlying causes are what set that sequence in motion. Listing two separate cancers is unusual and it does not say which mattered more.

"Metastatic lung cancer" as reported is also less specific than it sounds. Metastatic means cancer has spread from where it started to a distant site. Whether the certificate meant a lung cancer that had spread, or another cancer that had reached the lungs, is not something the reporting resolves. We are not going to guess. Our page on cancer diagnosis explains why the site of origin, not the site found, names a cancer.

What acute myeloid leukemia is

Bone marrow makes blood. A blood stem cell matures step by step into a red cell that carries oxygen, a platelet that helps clotting, or one of several white cells that fight infection.

AML interrupts that. NCI describes it as a varied group of blood cancers in which immature myeloid cells, called blasts, multiply out of control in the marrow.

The damage is largely crowding. As blasts fill the marrow, normal production fails. NCI notes that low white cells, low red cells and low platelets are all common, because the leukemia cells get in the way of normal blood formation.

That explains the symptoms directly. Weakness and pallor come from the missing red cells. Fever and infection come from the missing functional white cells. Bleeding comes from the missing platelets.

NCI adds a detail worth knowing: the symptoms of acute leukemia often build over just four to six weeks before diagnosis. This is not a slow disease.

How it is diagnosed

A blood sample can suggest the diagnosis. A bone marrow biopsy settles it.

NCI states that a blast count of 20% or more, in blood or marrow, is required, with exceptions for a few specific chromosome rearrangements. Flow cytometry, which reads the proteins on the surface of the cells, is the primary tool for separating AML from other leukemias. NCI is explicit that looking at cell shape alone is not adequate.

Genetics then does the rest of the work. About half of people with AML have a chromosomal abnormality, and NCI calls conventional cytogenetic analysis mandatory. Molecular testing for changes in genes including NPM1, FLT3, CEBPA and RUNX1 is now routine. NCI describes cytogenetic and molecular findings as the strongest prognostic information available.

Our overview of leukemia covers how the acute and chronic types differ.

What treatment aims at

NCI's guidance is unusually direct: treatment should be aggressive enough to achieve complete remission, because a partial remission offers no substantial survival benefit.

Roughly 60% to 70% of adults reach complete remission after induction therapy, the first intensive round. More than 25% of adults with AML, which is about 45% of those who reach remission, can be expected to survive three years or more and may be cured.

There is no screening test for AML, and NCI does not publish evidence-based prevention information for leukemia.

When to get checked

The pattern that matters is speed and combination, not any one symptom.

• Tiredness or weakness that has come on over weeks rather than months
• Unusual paleness
• Fever or repeated infections with no clear source
• Bruising easily, or bruises in places you have not knocked
• Bleeding gums, frequent nosebleeds, or cuts that keep oozing
• Small flat red spots on the skin that do not fade under pressure

Any one of these has ordinary explanations. Several arriving together over a month is a reason for a blood count, which is a simple and quick test.

The survival picture

About 22,720 new AML diagnoses and about 11,500 deaths are expected in the United States in 2026. Those two counts are American Cancer Society projections carried on the SEER stat facts page. The median age at diagnosis, 70, is SEER's own measurement.

Five-year relative survival is 33.4% for people diagnosed from 2016 through 2022.

That figure pools every subtype and every age together, and age moves it enormously. It describes a large group and not any individual, and it lags behind treatments introduced in the last few years.

What this does not mean

Reubens was 70, close to the median age at AML diagnosis. That is a coincidence of statistics, not an explanation of his case.

The presence of two cancers on a death certificate does not tell you they were related, or which came first. The reporting does not establish either.

And a person who keeps an illness private is making a choice about their own life. It is not a model for anyone else, and it is not a criticism of people who choose otherwise. Our page on the emotional side of cancer covers what that decision can involve.

Sources

• The Guardian: Paul Reubens, actor best known for playing Pee-wee Herman, dies aged 70
• TODAY (NBC News): Paul Reubens died of acute hypoxic respiratory failure, death certificate shows
• NCI PDQ: Acute Myeloid Leukemia Treatment (Health Professional Version)
• NCI SEER Stat Facts: Acute Myeloid Leukemia

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

See an error, old source, or unclear wording? Tell us.